Visible node/edge number:
Node colors:
Node labels:

show label of nodes with degree >=

Node sizes:
Edge colors:
Edge widths factor:
Layout:

gravity >=

edgeLength =

GRN in network:

Notice: IE browser need to manually refresh (F5) this page after resetting the network.

This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.

"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.

miRNA-gene regulations

(Download full result)

Num microRNA           Gene miRNA log2FC miRNA pvalue Gene log2FC Gene pvalue Interaction Correlation beta Correlation P-value PMID Reported in cancer studies
1 hsa-let-7b-5p AIFM1 0.06 0.7814 -0.33 0.06746 miRNATAP -0.19 0.00202 NA
2 hsa-let-7i-5p AIFM1 0.8 3.0E-5 -0.33 0.06746 miRNATAP -0.23 0.00049 NA
3 hsa-miR-125a-5p AIFM1 -0.88 0.00021 -0.33 0.06746 miRanda -0.12 0.02693 NA
4 hsa-miR-125b-5p AIFM1 -0.51 0.13327 -0.33 0.06746 miRNATAP -0.22 0 NA
5 hsa-miR-143-5p AIFM1 -0.45 0.12536 -0.33 0.06746 miRNATAP -0.11 0.01208 NA
6 hsa-miR-145-5p AIFM1 -1.75 2.0E-5 -0.33 0.06746 miRNATAP -0.1 0.00169 20332243 Artificial overexpression of miR145 by using adenoviral vectors in prostate cancer PC-3 and DU145 cells significantly downregulated BNIP3 together with the upregulation of AIF reduced cell growth and increased cell death
7 hsa-miR-199a-5p AIFM1 0.37 0.23266 -0.33 0.06746 miRanda -0.21 0 NA
8 hsa-miR-10a-5p AKT2 -0.47 0.1488 -0.01 0.9227 mirMAP -0.07 0.03038 NA
9 hsa-miR-21-5p AKT2 1.75 0 -0.01 0.9227 miRNAWalker2 validate -0.15 0.00352 NA
10 hsa-miR-29a-3p AKT2 -0.11 0.61501 -0.01 0.9227 MirTarget -0.1 0.02733 24076586 Furthermore a feed-back loop comprising of c-Myc miR-29 family and Akt2 were found in myeloid leukemogenesis
11 hsa-miR-29b-3p AKT2 -0.23 0.36746 -0.01 0.9227 MirTarget -0.14 0.00022 26512921; 26564501; 24076586 MicroRNA 29B mir 29b regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3;The expression of miR-29b was significantly upregualted by cisplatin treatmentwhile its target gene AKT2 was downregulated;Furthermore a feed-back loop comprising of c-Myc miR-29 family and Akt2 were found in myeloid leukemogenesis
12 hsa-miR-29c-3p AKT2 -1.62 0 -0.01 0.9227 MirTarget -0.07 0.02525 NA
13 hsa-miR-502-5p AKT2 -0.26 0.52045 -0.01 0.9227 mirMAP -0.09 0.00016 NA
14 hsa-miR-106b-5p AKT3 1.71 0 -0.75 0.06936 miRNATAP -0.37 7.0E-5 NA
15 hsa-miR-107 AKT3 0.9 5.0E-5 -0.75 0.06936 PITA; miRanda -0.6 0 NA
16 hsa-miR-15a-5p AKT3 1.04 0 -0.75 0.06936 miRNAWalker2 validate; miRTarBase; miRNATAP -0.27 0.04887 NA
17 hsa-miR-15b-5p AKT3 1.62 0 -0.75 0.06936 miRNATAP -0.36 0.00041 NA
18 hsa-miR-16-5p AKT3 1.01 1.0E-5 -0.75 0.06936 miRNAWalker2 validate; miRTarBase; miRNATAP -0.47 0.00031 NA
19 hsa-miR-17-3p AKT3 1.31 0 -0.75 0.06936 miRNATAP -0.52 0 NA
20 hsa-miR-17-5p AKT3 1.66 0 -0.75 0.06936 TargetScan; miRNATAP -0.28 0.0027 NA
21 hsa-miR-20a-5p AKT3 1.45 0 -0.75 0.06936 miRNATAP -0.25 0.01166 NA
22 hsa-miR-29a-3p AKT3 -0.11 0.61501 -0.75 0.06936 miRNATAP -0.41 0.00212 NA
23 hsa-miR-29b-3p AKT3 -0.23 0.36746 -0.75 0.06936 miRNATAP -0.34 0.00361 26512921 MicroRNA 29B mir 29b regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3
24 hsa-miR-3065-5p AKT3 -0.24 0.63312 -0.75 0.06936 mirMAP -0.13 0.03593 NA
25 hsa-miR-32-3p AKT3 0.58 0.11837 -0.75 0.06936 mirMAP -0.32 0.00023 NA
26 hsa-miR-320b AKT3 1.11 0.0005 -0.75 0.06936 PITA; miRanda; miRNATAP -0.26 0.0039 NA
27 hsa-miR-335-3p AKT3 2.52 0 -0.75 0.06936 mirMAP -0.22 0.00074 NA
28 hsa-miR-33a-3p AKT3 0.35 0.32171 -0.75 0.06936 mirMAP -0.38 2.0E-5 NA
29 hsa-miR-362-3p AKT3 -0.03 0.91378 -0.75 0.06936 miRanda -0.38 4.0E-5 NA
30 hsa-miR-362-5p AKT3 -0.35 0.35491 -0.75 0.06936 PITA; TargetScan; miRNATAP -0.23 0.00253 NA
31 hsa-miR-3662 AKT3 1.83 0.0054 -0.75 0.06936 mirMAP -0.15 0.01121 NA
32 hsa-miR-421 AKT3 1.81 0 -0.75 0.06936 miRanda; mirMAP -0.21 0.01124 NA
33 hsa-miR-424-5p AKT3 1.09 0.00042 -0.75 0.06936 miRNATAP -0.23 0.01426 26315541 Silencing Akt3 and E2F3 by siRNA pheno-copied the effect of ectopic miR-424 on HCC growth; Whereas overexpression of Akt3 and E2F3 attenuated the effect of miR-424 on HCC growth
34 hsa-miR-501-3p AKT3 0.73 0.02704 -0.75 0.06936 miRNATAP -0.39 1.0E-5 NA
35 hsa-miR-502-3p AKT3 -0.16 0.55747 -0.75 0.06936 miRNATAP -0.5 0 NA
36 hsa-miR-505-3p AKT3 0.83 0.00112 -0.75 0.06936 mirMAP -0.35 0.00235 22051041 We also find that Akt3 correlate inversely with miR-505 modulates drug sensitivity in MCF7-ADR
37 hsa-miR-548v AKT3 -0.16 0.70867 -0.75 0.06936 miRNATAP -0.27 0.00031 NA
38 hsa-miR-577 AKT3 0.91 0.22561 -0.75 0.06936 mirMAP -0.23 0 NA
39 hsa-miR-616-5p AKT3 0.83 0.03478 -0.75 0.06936 mirMAP -0.27 0.00041 NA
40 hsa-miR-93-5p AKT3 1.75 0 -0.75 0.06936 miRNATAP -0.2 0.03321 NA
41 hsa-miR-23a-3p APAF1 1.11 0 0.3 0.22769 miRNATAP -0.49 0 24992592; 24249161 Luciferase assay was performed to verify a putative target site of miR-23a in the 3'-UTR of apoptosis protease activating factor 1 APAF1 mRNA; The expression levels of miR-23a and APAF1 in CRC cell lines SW480 and SW620 and clinical samples were assessed using reverse transcription-quantitative real-time PCR RT-qPCR and Western blot; Moreover miR-23a up-regulation was coupled with APAF1 down-regulation in CRC tissue samples;We found that the expression of miR-23a was increased and the level of apoptosis-activating factor-1 APAF-1 was decreased in 5-FU-treated colon cancer cells compared to untreated cells; APAF-1 as a target gene of miR-23a was identified and miR-23a antisense-induced increase in the activation of caspase-9 was observed
42 hsa-miR-23b-3p APAF1 -0.29 0.18665 0.3 0.22769 miRNATAP -0.54 0 NA
43 hsa-miR-27a-3p APAF1 1.3 0 0.3 0.22769 miRNATAP -0.39 0 NA
44 hsa-miR-27b-3p APAF1 0.08 0.72527 0.3 0.22769 miRNATAP -0.48 0 NA
45 hsa-miR-708-3p APAF1 0.62 0.27536 0.3 0.22769 mirMAP -0.24 0 NA
46 hsa-miR-944 APAF1 3.33 0.01778 0.3 0.22769 miRNATAP -0.13 0 NA
47 hsa-miR-125a-3p ATM 1.2 0.00164 -0.39 0.08341 miRanda -0.13 0.00188 NA
48 hsa-miR-203a-3p ATM 1.45 0.03941 -0.39 0.08341 MirTarget -0.14 0 24145123; 27542403 miR 203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase; In silico analysis identified ataxia telangiectasia mutated ATM a primary mediator of the DNA damage response as a potential target of miR-203; Using TCGA database we identified a significant reverse correlation of miR-203 and ATM expression in CRC tissues; We validated ATM as a bona fide target of miR-203 in CRC cells; Mutation of the putative miR-203 binding site in the 3' untranslated region 3'UTR of the ATM mRNA abolished the inhibitory effect of miR-203 on ATM;MiR 203 inhibits tumor invasion and metastasis in gastric cancer by ATM; Our results showed that miR-203 was significantly downregulated in gastric cancer tissues and cells while ataxia telangiectasia mutated kinase ATM was upregulated in gastric cancer tissues and cells and was directly regulated by miR-203; ATM knockdown phenocopied the effect of miR-203 overexpression
49 hsa-miR-324-5p ATM 1.09 3.0E-5 -0.39 0.08341 miRanda -0.12 0.04523 NA
50 hsa-miR-34c-5p ATM 2.21 0.00038 -0.39 0.08341 miRanda -0.06 0.03026 NA
51 hsa-miR-590-5p ATM 1.04 0.00027 -0.39 0.08341 mirMAP -0.17 0.00247 NA
52 hsa-miR-944 ATM 3.33 0.01778 -0.39 0.08341 mirMAP -0.07 0 NA
53 hsa-miR-30a-5p BAX -1.72 0 1.23 0 miRNAWalker2 validate -0.15 0.00018 NA
54 hsa-miR-365a-3p BAX -0.89 0.00255 1.23 0 miRNAWalker2 validate -0.19 6.0E-5 24216611 MiR 365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro apoptotic regulator BAX
55 hsa-miR-15b-3p BCL2 1.76 0 -1.09 0.00317 mirMAP -0.24 0.00334 25594541; 26915294; 26884837; 18449891 MicroRNAs miRNAs encoded by the miR-15 cluster are known to induce G1 arrest and apoptosis by targeting G1 checkpoints and the anti-apoptotic B cell lymphoma 2 BCL-2 gene;As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;MiR 15b mediates liver cancer cells proliferation through targeting BCL 2; MiR-15b overexpression downregulated BCL2 mRNA and protein expression obviously P < 0.05; On the contrary miR-15b inhibitor transfection markedly reduced miR-15b expression in liver cancer cells P < 0.05 promoted tumor cell proliferation and increased BCL2 mRNA and protein expression; MiR-15b can inhibit HepG2 cell proliferation and down-regulate BCL2 mRNA and protein expression;miR 15b and miR 16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells; The downregulation of miR-15b and miR-16 in SGC7901/VCR cells was concurrent with the upregulation of Bcl-2 protein; Taken together our findings suggest that miR-15b and miR-16 could play a role in the development of MDR in gastric cancer cells at least in part by modulation of apoptosis via targeting BCL2
56 hsa-miR-16-2-3p BCL2 1.8 0 -1.09 0.00317 mirMAP -0.26 0.0023 NA
57 hsa-miR-17-5p BCL2 1.66 0 -1.09 0.00317 miRNAWalker2 validate; miRTarBase -0.2 0.01676 25435430 Combined overexpression of miR-16 and miR-17 greatly reduced Beclin-1 and Bcl-2 expressions respectively; miR-17 overexpression reduced cytoprotective autophagy by targeting Beclin-1 whereas overexpression of miR-16 potentiated paclitaxel induced apoptotic cell death by inhibiting anti-apoptotic protein Bcl-2
58 hsa-miR-181b-5p BCL2 1.64 0 -1.09 0.00317 miRNAWalker2 validate; miRTarBase -0.22 0.01271 25524579 Moreover we also found miR-181 reduction was associated with increased Bcl-2 levels and miR-181 was further suggested to exert its pro-apoptotic function mainly through targeting Bcl-2 expression
59 hsa-miR-192-5p BCL2 0.08 0.94106 -1.09 0.00317 miRNAWalker2 validate -0.07 0.00226 26550150 MicroRNA 192 regulates chemo resistance of lung adenocarcinoma for gemcitabine and cisplatin combined therapy by targeting Bcl 2; In this paper we try to test whether miR-192 regulates chemo-resistance in human carcinoma A549 mice model by targeting Bcl-2; MTT assay real-time RT-PCR western blotting assay were used to investigate miR-192 expression levels cell viability ratio and Bcl-2 protein expression levels; Bcl-2 mRNA and protein expression levels up-regulated in miR-192 inhibitor treated tumor; Bcl-2 is a key regulator for miR-192 related chemotherapy resistance; In this study we demonstrate that miR-192 regulates chemoresistance for gemcitabine and cisplatin combined chemotherapy in human adenocarcinoma lung cancer A549 cells and Bcl-2 is the target of miR-192
60 hsa-miR-196b-5p BCL2 5.59 0 -1.09 0.00317 miRNAWalker2 validate -0.1 0.01463 NA
61 hsa-miR-200a-5p BCL2 1.5 0.00264 -1.09 0.00317 mirMAP -0.21 5.0E-5 NA
62 hsa-miR-200b-3p BCL2 0.97 0.0595 -1.09 0.00317 miRNAWalker2 validate; miRTarBase; TargetScan; mirMAP -0.18 0.00034 NA
63 hsa-miR-200b-5p BCL2 0.97 0.05305 -1.09 0.00317 mirMAP -0.21 0.00019 NA
64 hsa-miR-200c-3p BCL2 1.28 0.0037 -1.09 0.00317 miRNAWalker2 validate; miRTarBase; mirMAP -0.23 0.00013 NA
65 hsa-miR-20a-3p BCL2 1.14 0.00045 -1.09 0.00317 mirMAP -0.22 0.00669 NA
66 hsa-miR-21-5p BCL2 1.75 0 -1.09 0.00317 miRNAWalker2 validate; miRTarBase -0.57 2.0E-5 21468550; 25994220; 25381586; 26555418; 23359184; 22964582; 21376256 BCL-2 up-regulation could be achieved by miR-21 overexpression which prevented T24 cells from apoptosis induced by doxorubicin; Furthermore the miR-21 induced BCL-2 up-regulation could be cancelled by the PI3K inhibitor LY294002;Meanwhile miR-21 loss reduced STAT3 and Bcl-2 activation causing an increase in the apoptosis of tumour cells in CAC mice;Changes in the sensitivity of osteosarcoma cells to CDDP were examined after transfection with miR-21 mimics or anti-miR-21 or bcl-2 siRNA in combination with CDDP;The expression of Bax Bcl-2 and miR-21 in parental and paclitaxel-resistant cells was detected by RT-PCR and Western blotting;Resveratrol induces apoptosis of pancreatic cancers cells by inhibiting miR 21 regulation of BCL 2 expression; We also used Western blot to measure BCL-2 protein levels after down-regulation of miR-21 expression; Besides down-regulation of miR-21 expression can inhibit BCL-2 expression in PANC-1 CFPAC-1 and MIA Paca-2 cells; Over-expression of miR-21 expression can reverse down-regulation of BCL-2 expression and apoptosis induced by resveratrol; In this study we demonstrated that the effect of resveratrol on apoptosis is due to inhibiting miR-21 regulation of BCL-2 expression;Tumors harvested from these lungs have elevated levels of oncogenic miRNAs miR-21 and miR-155; are deficient for p53-regulated miRNAs; and have heightened expression of miR-34 target genes such as Met and Bcl-2;Bcl 2 upregulation induced by miR 21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa 2 pancreatic cancer cells; However the roles and mechanisms of miRNA miR-21 in regulation of Bcl-2 in pancreatic cancer remain to be elucidated; Then luciferase activity was observed after miR-21 mimics and pRL-TK plasmids containing wild-type and mutant 3'UTRs of Bcl-2 mRNA were co-transfected; Cells transfected with miR-21 inhibitor revealed an opposite trend. There was a significant increase in luciferase activity in the cells transfected with the wild-type pRL-TK plasmid in contrast to those transfected with the mutant one indicating that miR-21 promotes Bcl-2 expression by binding directly to the 3'UTR of Bcl-2 mRNA; Upregulation of Bcl-2 directly induced by miR-21 is associated with apoptosis chemoresistance and proliferation of MIA PaCa-2 pancreatic cancer cells
67 hsa-miR-215-5p BCL2 0.72 0.57378 -1.09 0.00317 miRNAWalker2 validate -0.07 0.00067 NA
68 hsa-miR-24-2-5p BCL2 1.25 0 -1.09 0.00317 miRNAWalker2 validate; miRTarBase -0.22 0.0345 NA
69 hsa-miR-29a-5p BCL2 0.59 0.02301 -1.09 0.00317 mirMAP -0.28 0.00622 20041405 Subsequent investigation characterized two antiapoptotic molecules Bcl-2 and Mcl-1 as direct targets of miR-29; Furthermore silencing of Bcl-2 and Mcl-1 phenocopied the proapoptotic effect of miR-29 whereas overexpression of these proteins attenuated the effect of miR-29
70 hsa-miR-3065-5p BCL2 -0.24 0.63312 -1.09 0.00317 mirMAP -0.13 0.01807 NA
71 hsa-miR-335-3p BCL2 2.52 0 -1.09 0.00317 mirMAP -0.17 0.00598 NA
72 hsa-miR-338-5p BCL2 -1.2 0.01003 -1.09 0.00317 PITA -0.12 0.0383 NA
73 hsa-miR-34a-5p BCL2 0.79 0.00024 -1.09 0.00317 miRNAWalker2 validate; miRTarBase -0.27 0.02855 24565525; 23155233; 24444609; 20687223; 22623155; 24988056; 18803879; 19714243; 25053345; 20433755; 21399894; 22964582; 23862748 In vitro and in vivo experiments showed that miR-34a and DOX can be efficiently encapsulated into HA-CS NPs and delivered into tumor cells or tumor tissues and enhance anti-tumor effects of DOX by suppressing the expression of non-pump resistance and anti-apoptosis proto-oncogene Bcl-2;The miR-34a expression levels in cells after irradiation at 30 and 60 Gy were 0.17- and 18.7-times the BCL2 and caspase-9 expression levels respectively;Functional analyses further indicate that restoration of miR-34a inhibits B cell lymphoma-2 Bcl-2 protein expression to withdraw the survival advantage of these resistant NSCLC cells;Thus in PC3PR cells reduced expression of miR-34a confers paclitaxel resistance via up-regulating SIRT1 and Bcl2 expression; MiR-34a and its downstream targets SIRT1 and Bcl2 play important roles in the development of paclitaxel resistance all of which can be useful biomarkers and promising therapeutic targets for the drug resistance in hormone-refractory prostate cancer;MiR 34a inhibits proliferation and migration of breast cancer through down regulation of Bcl 2 and SIRT1; In this study we aimed to determine the effect of miR-34a on the growth of breast cancer and to investigate whether its effect is achieved by targeting Bcl-2 and SIRT1; Bcl-2 and SIRT1 as the targets of miR-34a were found to be in reverse correlation with ectopic expression of miR-34a;Target analysis indicated that micro RNA miR-34a directly regulates Bcl-2 and miR-34a overexpression decreased Bcl-2 protein level in gastric cancer cells; We also found that luteolin upregulates miR-34a expression and downregulates Bcl-2 expression; Based on these results we can draw the conclusion that luteolin partly decreases Bcl-2 expression through upregulating miR-34a expression;miR-34 targets Notch HMGA2 and Bcl-2 genes involved in the self-renewal and survival of cancer stem cells; Human gastric cancer cells were transfected with miR-34 mimics or infected with the lentiviral miR-34-MIF expression system and validated by miR-34 reporter assay using Bcl-2 3'UTR reporter; Human gastric cancer Kato III cells with miR-34 restoration reduced the expression of target genes Bcl-2 Notch and HMGA2; Bcl-2 3'UTR reporter assay showed that the transfected miR-34s were functional and confirmed that Bcl-2 is a direct target of miR-34; The mechanism of miR-34-mediated suppression of self-renewal appears to be related to the direct modulation of downstream targets Bcl-2 Notch and HMGA2 indicating that miR-34 may be involved in gastric cancer stem cell self-renewal/differentiation decision-making;Among the target proteins regulated by miR-34 are Notch pathway proteins and Bcl-2 suggesting the possibility of a role for miR-34 in the maintenance and survival of cancer stem cells; Our data support the view that miR-34 may be involved in pancreatic cancer stem cell self-renewal potentially via the direct modulation of downstream targets Bcl-2 and Notch implying that miR-34 may play an important role in pancreatic cancer stem cell self-renewal and/or cell fate determination;Manipulating miR-34a in prostate cancer cells confirms that this miRNA regulates BCL-2 and may in part regulate response to docetaxel;For instance miR-34a up-regulation corresponded with a down-regulation of BCL2 protein; Treating Par-4-overexpressing HT29 cells with a miR-34a antagomir functionally reversed both BCL2 down-regulation and apoptosis by 5-FU;Quantitative PCR and western analysis confirmed decreased expression of two genes BCL-2 and CCND1 in docetaxel-resistant cells which are both targeted by miR-34a;Tumors harvested from these lungs have elevated levels of oncogenic miRNAs miR-21 and miR-155; are deficient for p53-regulated miRNAs; and have heightened expression of miR-34 target genes such as Met and Bcl-2;MicroRNA 34a targets Bcl 2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment; HCC tissues with lower miR-34a expression displayed higher expression of Bcl-2 protein than those with high expression of miR-34a; therefore an inverse correlation is evident between the miR-34a level and Bcl-2 expression; Bioinformatics and luciferase reporter assays revealed that miR-34a binds the 3'-UTR of the Bcl-2 mRNA and represses its translation; Western blotting analysis and qRT-PCR confirmed that Bcl-2 is inhibited by miR-34a overexpression; Functional analyses indicated that the restoration of miR-34a reduced cell viability promoted cell apoptosis and potentiated sorafenib-induced apoptosis and toxicity in HCC cell lines by inhibiting Bcl-2 expression
74 hsa-miR-375 BCL2 -2.95 0.0057 -1.09 0.00317 miRNAWalker2 validate -0.05 0.03382 26381132; 26697569; 25613180 The levels of miR-375 Bax and Bcl-2 protein expression in treated cells were determined by Western blot and RT-PCR; Moreover compared to control group the expression of Bcl-2 and miR-375 decreases with formononetin in the U2OS cells while Bax increases;Exosome Carried microRNA 375 Inhibits Cell Progression and Dissemination via Bcl 2 Blocking in Colon Cancer; RT-PCR for Bcl-2 expression showed that Bcl-2 is down-regulated for miR-375 inhibitor and up-regulated for the miR-375 mimic a result confirmed by Western blotting; The present study brings to the forefront new data that suggest miR-375 as a new player in controlling the pathways responsible for inhibiting the natural history of CRC tumor cells via the Bcl-2 pathway;mRNA levels of ERα Bcl-2 and miR-375 were quantified using real-time polymerase chain reaction; After treatment with biochanin A ERα miR-375 and Bcl-2 expression was significantly upregulated
75 hsa-miR-429 BCL2 1.4 0.009 -1.09 0.00317 miRNAWalker2 validate; miRTarBase; PITA; mirMAP -0.2 3.0E-5 23999873; 26513239; 26511969 MiR 429 up regulation induces apoptosis and suppresses invasion by targeting Bcl 2 and SP 1 in esophageal carcinoma; Subsequent Western blotting and luciferase reporter assays showed that miR-429 can bind to putative binding sites within the Bcl-2 and SP1 mRNA 3' untranslated regions UTRs to reduce their expression; Up-regulation of miR-429 inhibits invasion and promotes apoptosis in EC cells by targeting Bcl-2 and SP1; Our findings suggest that Bcl-2 and SP1 may serve as major targets of miR-429;MiR 429 Induces Gastric Carcinoma Cell Apoptosis Through Bcl 2; Here we studied the levels of miR-429 and anti-apoptotic protein Bcl-2 in GC specimens; We performed bioinformatics analyses and used luciferase-reporter assay to analyze the relationship between miR-429 and Bcl-2 in GC cells; MiR-429 levels were significantly decreased and Bcl-2 levels were significantly increased in GC specimens compared to the paired adjacent non-tumor gastric tissue; Moreover the levels of miR-429 and Bcl-2 inversely correlated in GC specimens; Bioinformatics analyses showed that miR-429 targeted the 3'-UTR of Bcl-2 mRNA to inhibit its translation which was confirmed by luciferase-reporter assay;MiR 429 induces apoptosis of glioblastoma cell through Bcl 2; Here we analyzed the levels of miR-429 and anti-apoptotic protein Bcl-2 in GBM specimens; We combined bioinformatics analyses and luciferase reporter assay to determine the relationship between miR-429 and Bcl-2 in GBM cells; We found that miR-429 levels were significantly decreased and Bcl-2 levels were significantly increased in GBM specimens compared to the paired adjacent non-tumor brain tissue; Moreover the levels of miR-429 and Bcl-2 inversely correlated; MiR-429 targeted the 3'-UTR of Bcl-2 mRNA to inhibit its translation
76 hsa-miR-455-5p BCL2 1.2 7.0E-5 -1.09 0.00317 mirMAP -0.35 4.0E-5 NA
77 hsa-miR-577 BCL2 0.91 0.22561 -1.09 0.00317 PITA -0.1 0.00537 NA
78 hsa-miR-590-3p BCL2 1.12 0.00016 -1.09 0.00317 miRanda; mirMAP -0.2 0.02525 NA
79 hsa-miR-590-5p BCL2 1.04 0.00027 -1.09 0.00317 miRanda -0.2 0.03472 NA
80 hsa-miR-7-1-3p BCL2 0.71 0.04123 -1.09 0.00317 mirMAP -0.19 0.0132 NA
81 hsa-miR-7-5p BCL2 1.64 0.01244 -1.09 0.00317 miRNAWalker2 validate; miRTarBase; mirMAP -0.14 0.00068 26464649; 25862909; 21750649 Western blotting was used to evaluate the effect of miR-7 on Bcl2 in A549 and H460 cells; Moreover subsequent experiments showed that BCL-2 was downregulated by miR-7 at both transcriptional and translational levels; This study further extends the biological role of miR-7 in NSCLC A549 and H460 cells and identifies BCL-2 as a novel target possibly involved in miR-7-mediated growth suppression and apoptosis induction of NSCLC cells;miR-7 overexpression correlated with diminished BCL2 expression but there was no relationship between miR-7 and EGFR expression neither in tumour samples nor in the cell lines; Of the two postulated miR-7 target genes we examined BCL2 but not EGFR seems to be a possible miR-7 target in OC;Bioinformatics predictions revealed a potential binding site of miR-7 on 3'UTR of BCL-2 and it was further confirmed by luciferase assay; Moreover subsequent experiments showed that BCL-2 was downregulated by miR-7 at both transcriptional and translational levels; These results suggest that miR-7 regulates the expression of BCL-2 through direct 3'UTR interactions
82 hsa-let-7b-5p BCL2L1 0.06 0.7814 0.21 0.39578 miRNATAP -0.31 0.00027 26915294; 20347499 As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;The let 7 family of microRNAs inhibits Bcl xL expression and potentiates sorafenib induced apoptosis in human hepatocellular carcinoma; The effect of let-7 on Bcl-xL expression was examined by Western blot and a reporter assay; Microarray analysis followed by in silico target prediction identified let-7 microRNAs as being downregulated in Huh7 hepatoma cells in comparison with primary human hepatocytes as well as possessing a putative target site in the bcl-xl mRNA
83 hsa-let-7c-5p BCL2L1 -0.5 0.20685 0.21 0.39578 miRNAWalker2 validate; miRTarBase -0.2 1.0E-5 20347499 Over-expression of let-7c or let-7g led to a clear decrease of Bcl-xL expression in Huh7 and HepG2 cell lines; Reporter assays revealed direct post-transcriptional regulation involving let-7c or let-7g and the 3'-untranslated region of bcl-xl mRNA
84 hsa-let-7i-5p BCL2L1 0.8 3.0E-5 0.21 0.39578 miRNATAP -0.21 0.02883 NA
85 hsa-miR-133a-3p BCL2L1 -3.07 0 0.21 0.39578 miRNAWalker2 validate -0.08 0.00328 23756231 Furthermore bioinformatic prediction and experimental validation were applied to identify target genes of miR-133a and the results revealed that the anti-tumor effect of miR-133a was probably due to targeting and repressing of Bcl-xL and Mcl-1 expression
86 hsa-miR-149-5p BCL2L1 0.71 0.29685 0.21 0.39578 mirMAP -0.17 0 NA
87 hsa-miR-214-3p BCL2L1 1.01 0.00625 0.21 0.39578 mirMAP -0.13 0.00824 NA
88 hsa-miR-23b-3p BCL2L1 -0.29 0.18665 0.21 0.39578 miRNAWalker2 validate -0.39 0 NA
89 hsa-miR-342-3p BCL2L1 0.32 0.26915 0.21 0.39578 PITA; miRanda; miRNATAP -0.15 0.01448 NA
90 hsa-miR-624-5p BIRC2 1.03 0.00109 0.15 0.34408 MirTarget -0.08 0.03344 NA
91 hsa-miR-24-2-5p BIRC3 1.25 0 -0.43 0.44493 MirTarget -0.4 0.01021 NA
92 hsa-miR-28-3p BIRC3 -0.73 0.00035 -0.43 0.44493 MirTarget -0.4 0.04567 NA
93 hsa-miR-369-3p BIRC3 0.32 0.35899 -0.43 0.44493 MirTarget; miRNATAP -0.26 0.02353 NA
94 hsa-miR-496 BIRC3 0.57 0.16341 -0.43 0.44493 mirMAP -0.24 0.03348 NA
95 hsa-miR-651-5p BIRC3 0.67 0.06005 -0.43 0.44493 MirTarget -0.25 0.02779 NA
96 hsa-miR-491-5p CAPN1 -0.69 0.03136 0.47 0.04786 miRanda -0.18 0.0005 NA
97 hsa-miR-107 CAPN2 0.9 5.0E-5 -0.59 0.00617 miRanda -0.2 0.00395 NA
98 hsa-miR-20a-3p CAPN2 1.14 0.00045 -0.59 0.00617 MirTarget -0.11 0.01449 NA
99 hsa-miR-320a CAPN2 0.59 0.0119 -0.59 0.00617 miRanda -0.26 6.0E-5 NA
100 hsa-miR-320b CAPN2 1.11 0.0005 -0.59 0.00617 miRanda -0.16 0.00048 NA
101 hsa-miR-421 CAPN2 1.81 0 -0.59 0.00617 miRanda -0.18 2.0E-5 NA
102 hsa-miR-7-5p CAPN2 1.64 0.01244 -0.59 0.00617 miRNAWalker2 validate -0.06 0.0095 NA
103 hsa-miR-125b-5p CASP10 -0.51 0.13327 0.32 0.44988 mirMAP -0.45 0 NA
104 hsa-miR-129-5p CASP10 -2.57 0 0.32 0.44988 mirMAP -0.15 0.0057 NA
105 hsa-miR-145-3p CASP10 -1.65 2.0E-5 0.32 0.44988 mirMAP -0.22 0.00525 NA
106 hsa-miR-145-5p CASP10 -1.75 2.0E-5 0.32 0.44988 mirMAP -0.21 0.00404 NA
107 hsa-miR-34c-3p CASP10 2.25 9.0E-5 0.32 0.44988 mirMAP -0.32 0 NA
108 hsa-miR-374a-3p CASP10 0.04 0.85148 0.32 0.44988 mirMAP -0.31 0.02523 NA
109 hsa-miR-452-5p CASP10 2.09 0.00026 0.32 0.44988 mirMAP -0.28 0 NA
110 hsa-miR-744-3p CASP10 1.4 0.00097 0.32 0.44988 mirMAP -0.35 0 NA
111 hsa-let-7b-5p CASP3 0.06 0.7814 0.56 0.00075 MirTarget; miRNATAP -0.11 0.04898 NA
112 hsa-let-7c-5p CASP3 -0.5 0.20685 0.56 0.00075 MirTarget -0.09 0.00144 NA
113 hsa-miR-129-5p CASP3 -2.57 0 0.56 0.00075 mirMAP -0.07 0.0012 23744359 The intrinsic apoptotic pathway triggered by miR-129 was activated by cleavage of caspase-9 and caspase-3
114 hsa-miR-193b-5p CASP3 0.61 0.13924 0.56 0.00075 MirTarget -0.09 0.0012 NA
115 hsa-miR-369-3p CASP6 0.32 0.35899 0.39 0.09276 MirTarget -0.11 0.01531 NA
116 hsa-miR-129-5p CASP7 -2.57 0 0.22 0.30127 miRanda -0.06 0.03003 NA
117 hsa-miR-23b-3p CASP7 -0.29 0.18665 0.22 0.30127 MirTarget -0.19 0.00671 NA
118 hsa-miR-9-3p CASP7 0.33 0.54111 0.22 0.30127 MirTarget -0.1 0.00051 NA
119 hsa-miR-129-5p CASP8 -2.57 0 1.08 0 miRanda -0.14 0 NA
120 hsa-miR-143-3p CASP8 -0.66 0.04832 1.08 0 MirTarget -0.19 3.0E-5 NA
121 hsa-miR-20b-5p CASP8 -0.75 0.1377 1.08 0 MirTarget -0.06 0.04587 NA
122 hsa-miR-193b-3p CASP9 0.28 0.45126 -0.31 0.11004 miRNAWalker2 validate -0.17 0 NA
123 hsa-miR-103a-2-5p CFLAR 0.81 0.01999 0.07 0.73819 mirMAP -0.11 0.01177 NA
124 hsa-miR-130a-3p CFLAR 0.15 0.63374 0.07 0.73819 mirMAP -0.14 0.00421 NA
125 hsa-miR-130b-3p CFLAR 1.33 5.0E-5 0.07 0.73819 mirMAP -0.21 0 NA
126 hsa-miR-15b-5p CFLAR 1.62 0 0.07 0.73819 mirMAP -0.22 4.0E-5 NA
127 hsa-miR-16-5p CFLAR 1.01 1.0E-5 0.07 0.73819 mirMAP -0.17 0.01274 NA
128 hsa-miR-224-3p CFLAR 1.52 0.0065 0.07 0.73819 mirMAP -0.09 0.00145 NA
129 hsa-miR-224-5p CFLAR 2.76 0.00011 0.07 0.73819 MirTarget -0.06 0.00246 NA
130 hsa-miR-301a-3p CFLAR 1.45 1.0E-5 0.07 0.73819 mirMAP -0.2 1.0E-5 NA
131 hsa-miR-320b CFLAR 1.11 0.0005 0.07 0.73819 miRanda -0.11 0.02613 NA
132 hsa-miR-320c CFLAR 0.46 0.24061 0.07 0.73819 miRanda -0.11 0.01943 NA
133 hsa-miR-34c-5p CFLAR 2.21 0.00038 0.07 0.73819 miRanda -0.09 0.00022 NA
134 hsa-miR-455-5p CFLAR 1.2 7.0E-5 0.07 0.73819 miRanda -0.1 0.04815 NA
135 hsa-miR-484 CFLAR 0.71 0.00234 0.07 0.73819 mirMAP -0.16 0.0119 NA
136 hsa-miR-708-5p CFLAR 1.42 0.01096 0.07 0.73819 mirMAP -0.1 0.00027 NA
137 hsa-miR-9-5p CFLAR -0.2 0.76147 0.07 0.73819 mirMAP -0.13 0 NA
138 hsa-miR-152-3p CHUK 0.44 0.1617 -0.11 0.43611 MirTarget -0.17 0 NA
139 hsa-miR-195-5p CHUK -0.91 0.00151 -0.11 0.43611 miRNAWalker2 validate; MirTarget -0.13 0.00012 NA
140 hsa-miR-23a-3p CHUK 1.11 0 -0.11 0.43611 MirTarget -0.17 0.00056 NA
141 hsa-miR-23b-3p CHUK -0.29 0.18665 -0.11 0.43611 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.19 6.0E-5 NA
142 hsa-miR-342-3p CHUK 0.32 0.26915 -0.11 0.43611 miRanda -0.19 0 NA
143 hsa-miR-376c-3p CHUK -0.02 0.95345 -0.11 0.43611 MirTarget -0.08 0.00918 NA
144 hsa-miR-497-5p CHUK -0.8 0.0036 -0.11 0.43611 MirTarget -0.11 0.00273 NA
145 hsa-miR-655-3p CHUK 0.3 0.39642 -0.11 0.43611 MirTarget -0.08 0.00609 NA
146 hsa-miR-15b-3p CSF2RB 1.76 0 -0.2 0.59657 mirMAP -0.31 0.00012 NA
147 hsa-miR-19a-3p CSF2RB 1.27 0.00011 -0.2 0.59657 MirTarget -0.18 0.02841 NA
148 hsa-miR-30b-3p CSF2RB -0.27 0.40085 -0.2 0.59657 MirTarget -0.25 0.00393 NA
149 hsa-miR-452-3p CSF2RB 2.2 0.00185 -0.2 0.59657 mirMAP -0.13 0.00156 NA
150 hsa-miR-455-5p CSF2RB 1.2 7.0E-5 -0.2 0.59657 miRanda -0.2 0.02508 NA

Over-represented Gene Ontology Biological Process

NumGOOverlapSizeP ValueAdj. P Value
1 POSITIVE REGULATION OF RESPONSE TO STIMULUS 48 1929 1.224e-33 3.412e-30
2 INTRACELLULAR SIGNAL TRANSDUCTION 45 1572 1.466e-33 3.412e-30
3 REGULATION OF CELL DEATH 41 1472 1.985e-29 3.079e-26
4 CELLULAR RESPONSE TO ORGANIC SUBSTANCE 44 1848 3.152e-29 3.667e-26
5 CELL DEATH 36 1001 4.464e-29 4.155e-26
6 EXTRINSIC APOPTOTIC SIGNALING PATHWAY 19 99 6.974e-29 4.636e-26
7 POSITIVE REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING 22 179 6.502e-29 4.636e-26
8 REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING 23 233 5.618e-28 3.268e-25
9 POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS 40 1492 6.323e-28 3.269e-25
10 APOPTOTIC SIGNALING PATHWAY 24 289 2.231e-27 1.038e-24
11 POSITIVE REGULATION OF MOLECULAR FUNCTION 42 1791 2.666e-27 1.128e-24
12 IMMUNE SYSTEM PROCESS 43 1984 1.021e-26 3.958e-24
13 POSITIVE REGULATION OF CELL COMMUNICATION 39 1532 2.978e-26 1.066e-23
14 REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 40 1656 3.389e-26 1.126e-23
15 POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 32 876 1.092e-25 3.389e-23
16 REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 21 213 1.665e-25 4.843e-23
17 ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 17 95 2.609e-25 7.14e-23
18 ACTIVATION OF IMMUNE RESPONSE 25 427 9.726e-25 2.514e-22
19 NEGATIVE REGULATION OF CELL DEATH 31 872 1.867e-24 4.572e-22
20 RESPONSE TO CYTOKINE 29 714 2.254e-24 5.245e-22
21 RESPONSE TO OXYGEN CONTAINING COMPOUND 36 1381 3.057e-24 6.774e-22
22 ZYMOGEN ACTIVATION 17 112 5.246e-24 1.109e-21
23 EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS 13 39 1.819e-23 3.68e-21
24 REGULATION OF IMMUNE RESPONSE 30 858 2.172e-23 4.211e-21
25 ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY 10 13 2.93e-23 5.454e-21
26 POSITIVE REGULATION OF IMMUNE RESPONSE 26 563 3.995e-23 7.15e-21
27 REGULATION OF IMMUNE SYSTEM PROCESS 35 1403 7.796e-23 1.343e-20
28 POSITIVE REGULATION OF CATALYTIC ACTIVITY 35 1518 1.041e-21 1.73e-19
29 POSITIVE REGULATION OF PEPTIDASE ACTIVITY 17 154 1.528e-21 2.451e-19
30 POSITIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY 10 17 1.972e-21 3.058e-19
31 NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY 15 98 2.644e-21 3.969e-19
32 ACTIVATION OF INNATE IMMUNE RESPONSE 18 204 5.436e-21 7.904e-19
33 PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY 15 109 1.43e-20 2.016e-18
34 PROTEIN MATURATION 19 265 2.059e-20 2.781e-18
35 TOLL LIKE RECEPTOR SIGNALING PATHWAY 14 85 2.092e-20 2.781e-18
36 REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY 16 153 6.447e-20 7.969e-18
37 REGULATION OF PEPTIDASE ACTIVITY 21 392 6.508e-20 7.969e-18
38 REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY 10 22 6.469e-20 7.969e-18
39 POSITIVE REGULATION OF CELL DEATH 24 605 9.521e-20 1.136e-17
40 POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS 27 867 1.333e-19 1.55e-17
41 POSITIVE REGULATION OF INNATE IMMUNE RESPONSE 18 246 1.636e-19 1.857e-17
42 REGULATION OF PROTEOLYSIS 25 711 2.442e-19 2.705e-17
43 POSITIVE REGULATION OF DEFENSE RESPONSE 20 364 3.503e-19 3.79e-17
44 RESPONSE TO NITROGEN COMPOUND 26 859 1.555e-18 1.645e-16
45 CELLULAR RESPONSE TO CYTOKINE STIMULUS 23 606 1.758e-18 1.817e-16
46 NEGATIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY 16 200 5.077e-18 5.135e-16
47 REGULATION OF INNATE IMMUNE RESPONSE 19 357 5.67e-18 5.613e-16
48 REGULATION OF RESPONSE TO STRESS 31 1468 7.732e-18 7.495e-16
49 RESPONSE TO ABIOTIC STIMULUS 27 1024 9.178e-18 8.715e-16
50 NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS 10 34 1.271e-17 1.183e-15
51 IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY 18 323 2.136e-17 1.949e-15
52 CYTOKINE MEDIATED SIGNALING PATHWAY 20 452 2.409e-17 2.155e-15
53 POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS 27 1135 1.213e-16 1.065e-14
54 POSITIVE REGULATION OF PROTEOLYSIS 18 363 1.675e-16 1.417e-14
55 REGULATION OF APOPTOTIC SIGNALING PATHWAY 18 363 1.675e-16 1.417e-14
56 REGULATION OF KINASE ACTIVITY 23 776 3.9e-16 3.241e-14
57 RESPONSE TO MOLECULE OF BACTERIAL ORIGIN 17 321 4.375e-16 3.571e-14
58 POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY 14 171 5.372e-16 4.31e-14
59 I KAPPAB KINASE NF KAPPAB SIGNALING 11 70 5.555e-16 4.381e-14
60 POSITIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY 13 132 5.684e-16 4.408e-14
61 RESPONSE TO ENDOGENOUS STIMULUS 29 1450 5.868e-16 4.476e-14
62 CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND 23 799 7.323e-16 5.496e-14
63 PHOSPHORYLATION 27 1228 8.577e-16 6.335e-14
64 ACTIVATION OF PROTEIN KINASE ACTIVITY 16 279 1.026e-15 7.459e-14
65 REGULATION OF PHOSPHORUS METABOLIC PROCESS 30 1618 1.154e-15 8.263e-14
66 SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND 9 33 1.266e-15 8.792e-14
67 EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND 9 33 1.266e-15 8.792e-14
68 FC EPSILON RECEPTOR SIGNALING PATHWAY 13 142 1.496e-15 1.024e-13
69 RESPONSE TO TUMOR NECROSIS FACTOR 15 233 1.613e-15 1.088e-13
70 REGULATION OF RESPONSE TO CYTOKINE STIMULUS 13 144 1.8e-15 1.196e-13
71 NEURON APOPTOTIC PROCESS 9 35 2.305e-15 1.511e-13
72 REGULATION OF TRANSFERASE ACTIVITY 24 946 2.435e-15 1.574e-13
73 REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS 10 55 2.682e-15 1.709e-13
74 REGULATION OF DEFENSE RESPONSE 22 759 3.163e-15 1.989e-13
75 REGULATION OF PROTEIN MODIFICATION PROCESS 30 1710 5.123e-15 3.178e-13
76 RESPONSE TO BIOTIC STIMULUS 23 886 6.701e-15 4.102e-13
77 CELLULAR RESPONSE TO ABIOTIC STIMULUS 15 263 9.709e-15 5.867e-13
78 POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 24 1036 1.814e-14 1.068e-12
79 POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 24 1036 1.814e-14 1.068e-12
80 POSITIVE REGULATION OF KINASE ACTIVITY 18 482 2.303e-14 1.339e-12
81 PROTEIN PHOSPHORYLATION 23 944 2.574e-14 1.479e-12
82 POSITIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY 14 228 2.999e-14 1.702e-12
83 NUCLEOTIDE BINDING DOMAIN LEUCINE RICH REPEAT CONTAINING RECEPTOR SIGNALING PATHWAY 8 28 3.435e-14 1.926e-12
84 NEURON DEATH 9 47 4.309e-14 2.387e-12
85 PROTEOLYSIS 25 1208 5.658e-14 3.098e-12
86 MYD88 INDEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY 8 30 6.434e-14 3.481e-12
87 REGULATION OF TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY 9 50 7.861e-14 4.204e-12
88 ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY 13 195 9.438e-14 4.99e-12
89 RESPONSE TO BACTERIUM 18 528 1.093e-13 5.716e-12
90 CELLULAR RESPONSE TO MECHANICAL STIMULUS 10 80 1.413e-13 7.306e-12
91 CYTOPLASMIC PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY 8 33 1.514e-13 7.742e-12
92 FC RECEPTOR SIGNALING PATHWAY 13 206 1.915e-13 9.683e-12
93 PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS 30 1977 2.408e-13 1.205e-11
94 CELLULAR RESPONSE TO NITROGEN COMPOUND 17 505 7.235e-13 3.581e-11
95 POSITIVE REGULATION OF TRANSFERASE ACTIVITY 18 616 1.477e-12 7.235e-11
96 RESPONSE TO EXTERNAL STIMULUS 28 1821 1.597e-12 7.743e-11
97 T CELL RECEPTOR SIGNALING PATHWAY 11 146 2.301e-12 1.104e-10
98 REGULATION OF NECROTIC CELL DEATH 7 26 2.389e-12 1.134e-10
99 CELLULAR RESPONSE TO STRESS 26 1565 2.421e-12 1.138e-10
100 REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 16 470 3.214e-12 1.495e-10
101 INTRINSIC APOPTOTIC SIGNALING PATHWAY 11 152 3.583e-12 1.651e-10
102 REGULATION OF HYDROLASE ACTIVITY 24 1327 3.825e-12 1.745e-10
103 RESPONSE TO PEPTIDE 15 404 4.918e-12 2.221e-10
104 RESPONSE TO MECHANICAL STIMULUS 12 210 5.696e-12 2.548e-10
105 NEGATIVE REGULATION OF RESPONSE TO STIMULUS 24 1360 6.436e-12 2.852e-10
106 TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY 10 118 7.564e-12 3.32e-10
107 RESPONSE TO LIPID 20 888 7.815e-12 3.399e-10
108 RESPONSE TO HORMONE 20 893 8.651e-12 3.727e-10
109 POSITIVE REGULATION OF HYDROLASE ACTIVITY 20 905 1.101e-11 4.701e-10
110 EXECUTION PHASE OF APOPTOSIS 8 55 1.252e-11 5.296e-10
111 REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY 14 365 1.793e-11 7.514e-10
112 INFLAMMATORY RESPONSE 15 454 2.569e-11 1.067e-09
113 NEGATIVE REGULATION OF CELL COMMUNICATION 22 1192 2.686e-11 1.106e-09
114 HOMEOSTATIC PROCESS 23 1337 3.421e-11 1.396e-09
115 IMMUNE RESPONSE 21 1100 4.61e-11 1.865e-09
116 REGULATION OF CELL PROLIFERATION 24 1496 4.752e-11 1.906e-09
117 REGULATION OF NEURON DEATH 12 252 4.805e-11 1.911e-09
118 CELLULAR RESPONSE TO EXTERNAL STIMULUS 12 264 8.239e-11 3.249e-09
119 CELLULAR COMPONENT DISASSEMBLY INVOLVED IN EXECUTION PHASE OF APOPTOSIS 7 43 1.118e-10 4.373e-09
120 CELLULAR RESPONSE TO PEPTIDE 12 274 1.266e-10 4.909e-09
121 POSITIVE REGULATION OF GENE EXPRESSION 25 1733 1.582e-10 6.082e-09
122 CELLULAR GLUCOSE HOMEOSTASIS 8 75 1.645e-10 6.272e-09
123 REGULATION OF NECROPTOTIC PROCESS 5 11 1.779e-10 6.728e-09
124 REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND 7 46 1.843e-10 6.907e-09
125 RESPONSE TO INTERLEUKIN 1 9 115 1.856e-10 6.907e-09
126 PHOSPHATIDYLINOSITOL 3 PHOSPHATE BIOSYNTHETIC PROCESS 7 49 2.934e-10 1.083e-08
127 NIK NF KAPPAB SIGNALING 8 83 3.763e-10 1.379e-08
128 CELLULAR RESPONSE TO HORMONE STIMULUS 15 552 3.92e-10 1.425e-08
129 NECROTIC CELL DEATH 6 28 4.378e-10 1.579e-08
130 INTERLEUKIN 1 MEDIATED SIGNALING PATHWAY 5 13 4.929e-10 1.764e-08
131 RESPONSE TO WOUNDING 15 563 5.144e-10 1.827e-08
132 CELLULAR RESPONSE TO ENDOGENOUS STIMULUS 19 1008 6.001e-10 2.115e-08
133 CELLULAR RESPONSE TO INTERLEUKIN 1 8 88 6.051e-10 2.117e-08
134 REGULATION OF NEURON APOPTOTIC PROCESS 10 192 9.43e-10 3.274e-08
135 RESPONSE TO ORGANIC CYCLIC COMPOUND 18 917 9.902e-10 3.413e-08
136 T CELL APOPTOTIC PROCESS 5 15 1.144e-09 3.914e-08
137 T CELL HOMEOSTASIS 6 34 1.538e-09 5.225e-08
138 NEGATIVE REGULATION OF MOLECULAR FUNCTION 19 1079 1.861e-09 6.275e-08
139 REGULATION OF CATABOLIC PROCESS 16 731 2.149e-09 7.147e-08
140 STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE 8 103 2.15e-09 7.147e-08
141 ACTIVATION OF PROTEIN KINASE A ACTIVITY 5 17 2.345e-09 7.738e-08
142 INNATE IMMUNE RESPONSE ACTIVATING CELL SURFACE RECEPTOR SIGNALING PATHWAY 8 106 2.706e-09 8.866e-08
143 POSITIVE REGULATION OF NEURON DEATH 7 67 2.831e-09 9.21e-08
144 LYMPHOCYTE APOPTOTIC PROCESS 5 18 3.238e-09 1.046e-07
145 CHEMICAL HOMEOSTASIS 17 874 3.65e-09 1.171e-07
146 INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE 7 71 4.283e-09 1.365e-07
147 WOUND HEALING 13 470 5.467e-09 1.73e-07
148 CELLULAR RESPONSE TO CARBOHYDRATE STIMULUS 7 74 5.749e-09 1.807e-07
149 RESPONSE TO INORGANIC SUBSTANCE 13 479 6.856e-09 2.141e-07
150 PHOSPHATIDYLINOSITOL BIOSYNTHETIC PROCESS 8 120 7.262e-09 2.253e-07
151 NECROPTOTIC PROCESS 5 21 7.631e-09 2.351e-07
152 RESPONSE TO TOXIC SUBSTANCE 10 241 8.443e-09 2.585e-07
153 POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS 6 47 1.186e-08 3.608e-07
154 POSITIVE REGULATION OF BIOSYNTHETIC PROCESS 23 1805 1.21e-08 3.655e-07
155 LEUKOCYTE APOPTOTIC PROCESS 5 23 1.255e-08 3.768e-07
156 REGULATION OF EXECUTION PHASE OF APOPTOSIS 5 24 1.581e-08 4.717e-07
157 DEFENSE RESPONSE 19 1231 1.601e-08 4.745e-07
158 LYMPHOCYTE HOMEOSTASIS 6 50 1.742e-08 5.13e-07
159 POSITIVE REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS 6 51 1.969e-08 5.733e-07
160 PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING 5 25 1.972e-08 5.733e-07
161 MULTICELLULAR ORGANISMAL HOMEOSTASIS 10 272 2.665e-08 7.703e-07
162 POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 17 1004 2.842e-08 8.162e-07
163 REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS 7 95 3.337e-08 9.527e-07
164 PEPTIDYL SERINE MODIFICATION 8 148 3.777e-08 1.071e-06
165 POSITIVE REGULATION OF INTRACELLULAR TRANSPORT 11 370 4.471e-08 1.261e-06
166 REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS 6 59 4.822e-08 1.352e-06
167 CELL ACTIVATION 13 568 5.116e-08 1.425e-06
168 LEUKOCYTE DIFFERENTIATION 10 292 5.198e-08 1.44e-06
169 LEUKOCYTE HOMEOSTASIS 6 60 5.344e-08 1.471e-06
170 RENAL SYSTEM PROCESS 7 102 5.474e-08 1.498e-06
171 POSITIVE REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS 4 12 5.926e-08 1.612e-06
172 IMMUNE SYSTEM DEVELOPMENT 13 582 6.792e-08 1.837e-06
173 MYD88 DEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY 5 32 7.336e-08 1.94e-06
174 NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND 5 32 7.336e-08 1.94e-06
175 INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS 5 32 7.336e-08 1.94e-06
176 NEGATIVE REGULATION OF SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND 5 32 7.336e-08 1.94e-06
177 REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 21 1672 8.288e-08 2.179e-06
178 RESPONSE TO COBALT ION 4 13 8.538e-08 2.232e-06
179 NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS 17 1087 8.995e-08 2.338e-06
180 RESPONSE TO OXYGEN LEVELS 10 311 9.373e-08 2.423e-06
181 RENAL WATER HOMEOSTASIS 5 34 1.008e-07 2.568e-06
182 RESPONSE TO CARBOHYDRATE 8 168 1.01e-07 2.568e-06
183 INTRACELLULAR RECEPTOR SIGNALING PATHWAY 8 168 1.01e-07 2.568e-06
184 RESPONSE TO AMINO ACID 7 112 1.046e-07 2.644e-06
185 SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION 11 404 1.089e-07 2.738e-06
186 GLUCOSE HOMEOSTASIS 8 170 1.107e-07 2.754e-06
187 CARBOHYDRATE HOMEOSTASIS 8 170 1.107e-07 2.754e-06
188 TOLL LIKE RECEPTOR 9 SIGNALING PATHWAY 4 14 1.192e-07 2.935e-06
189 REGULATION OF MAP KINASE ACTIVITY 10 319 1.187e-07 2.935e-06
190 POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 7 121 1.779e-07 4.356e-06
191 CELLULAR RESPONSE TO GLUCAGON STIMULUS 5 38 1.8e-07 4.385e-06
192 LEUKOCYTE CELL CELL ADHESION 9 255 1.978e-07 4.794e-06
193 RESPONSE TO DRUG 11 431 2.083e-07 5.022e-06
194 INOSITOL LIPID MEDIATED SIGNALING 7 124 2.104e-07 5.046e-06
195 LYMPHOCYTE ACTIVATION 10 342 2.262e-07 5.398e-06
196 AGING 9 264 2.652e-07 6.295e-06
197 RESPONSE TO REACTIVE OXYGEN SPECIES 8 191 2.706e-07 6.392e-06
198 REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS 4 17 2.813e-07 6.61e-06
199 PHOSPHATIDYLINOSITOL METABOLIC PROCESS 8 193 2.93e-07 6.852e-06
200 RESPONSE TO OXIDATIVE STRESS 10 352 2.95e-07 6.863e-06
201 REGULATION OF CELLULAR PROTEIN LOCALIZATION 12 552 3.091e-07 7.155e-06
202 REGULATION OF CELL DIFFERENTIATION 19 1492 3.328e-07 7.666e-06
203 POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION 10 360 3.626e-07 8.311e-06
204 CELLULAR HOMEOSTASIS 13 676 3.793e-07 8.652e-06
205 REGULATION OF CYTOKINE PRODUCTION 12 563 3.814e-07 8.657e-06
206 RESPONSE TO ALKALOID 7 137 4.152e-07 9.378e-06
207 CELLULAR CHEMICAL HOMEOSTASIS 12 570 4.349e-07 9.776e-06
208 CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND 11 465 4.431e-07 9.911e-06
209 POSITIVE REGULATION OF MAPK CASCADE 11 470 4.924e-07 1.096e-05
210 NEGATIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 6 88 5.369e-07 1.184e-05
211 LYMPHOCYTE DIFFERENTIATION 8 209 5.37e-07 1.184e-05
212 POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 9 289 5.668e-07 1.244e-05
213 GLYCEROLIPID BIOSYNTHETIC PROCESS 8 211 5.772e-07 1.261e-05
214 RESPONSE TO GLUCAGON 5 48 5.981e-07 1.301e-05
215 NEGATIVE REGULATION OF CATALYTIC ACTIVITY 14 829 6.077e-07 1.315e-05
216 REGULATION OF INFLAMMATORY RESPONSE 9 294 6.54e-07 1.409e-05
217 RESPONSE TO GAMMA RADIATION 5 50 7.363e-07 1.579e-05
218 REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 8 220 7.914e-07 1.689e-05
219 CELL DEVELOPMENT 18 1426 8.387e-07 1.782e-05
220 POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY 5 53 9.894e-07 2.093e-05
221 POSITIVE REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS 4 23 1.031e-06 2.17e-05
222 HEMOSTASIS 9 311 1.044e-06 2.187e-05
223 LIPID PHOSPHORYLATION 6 99 1.078e-06 2.24e-05
224 REGULATION OF INTRACELLULAR TRANSPORT 12 621 1.074e-06 2.24e-05
225 REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 20 1784 1.14e-06 2.358e-05
226 POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION 11 514 1.185e-06 2.439e-05
227 RESPONSE TO RADIATION 10 413 1.264e-06 2.59e-05
228 LEUKOCYTE ACTIVATION 10 414 1.292e-06 2.624e-05
229 RESPONSE TO ACID CHEMICAL 9 319 1.288e-06 2.624e-05
230 PHOSPHOLIPID BIOSYNTHETIC PROCESS 8 235 1.299e-06 2.629e-05
231 CELLULAR RESPONSE TO BIOTIC STIMULUS 7 163 1.34e-06 2.7e-05
232 POSITIVE REGULATION OF PROTEIN IMPORT 6 104 1.441e-06 2.89e-05
233 REGULATION OF ORGANELLE ORGANIZATION 16 1178 1.521e-06 3.037e-05
234 MULTICELLULAR ORGANISMAL WATER HOMEOSTASIS 5 58 1.559e-06 3.1e-05
235 DEVELOPMENTAL PROGRAMMED CELL DEATH 4 26 1.727e-06 3.419e-05
236 RESPONSE TO METAL ION 9 333 1.835e-06 3.617e-05
237 RESPONSE TO VIRUS 8 247 1.885e-06 3.701e-05
238 PROTEIN OLIGOMERIZATION 10 434 1.973e-06 3.857e-05
239 REGULATION OF MAPK CASCADE 12 660 2.025e-06 3.926e-05
240 DNA CATABOLIC PROCESS 4 27 2.022e-06 3.926e-05
241 RESPONSE TO CORTICOSTEROID 7 176 2.237e-06 4.319e-05
242 PROTEIN HETEROOLIGOMERIZATION 6 113 2.342e-06 4.504e-05
243 POSITIVE REGULATION OF TRANSPORT 14 936 2.549e-06 4.882e-05
244 POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT 8 258 2.607e-06 4.971e-05
245 RESPONSE TO KETONE 7 182 2.795e-06 5.308e-05
246 REGULATION OF PROTEIN IMPORT 7 183 2.898e-06 5.482e-05
247 POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 17 1395 2.947e-06 5.551e-05
248 SINGLE ORGANISM CELL ADHESION 10 459 3.25e-06 6.097e-05
249 ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS 14 957 3.3e-06 6.166e-05
250 LIPOPOLYSACCHARIDE MEDIATED SIGNALING PATHWAY 4 31 3.588e-06 6.678e-05
251 RESPONSE TO ALCOHOL 9 362 3.631e-06 6.732e-05
252 WATER HOMEOSTASIS 5 70 3.991e-06 7.339e-05
253 REGULATION OF MEMBRANE PERMEABILITY 5 70 3.991e-06 7.339e-05
254 POSITIVE REGULATION OF CYTOKINE PRODUCTION 9 370 4.337e-06 7.944e-05
255 RESPONSE TO UV 6 126 4.411e-06 8.017e-05
256 NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 6 126 4.411e-06 8.017e-05
257 NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS 9 372 4.53e-06 8.202e-05
258 REGULATION OF CYTOPLASMIC TRANSPORT 10 481 4.917e-06 8.867e-05
259 POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT 8 282 5.027e-06 8.996e-05
260 REGULATION OF LIPID METABOLIC PROCESS 8 282 5.027e-06 8.996e-05
261 POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS 6 129 5.054e-06 9.01e-05
262 REGULATION OF CELL ACTIVATION 10 484 5.193e-06 9.223e-05
263 IMMUNE EFFECTOR PROCESS 10 486 5.385e-06 9.528e-05
264 REGULATION OF INTRACELLULAR PROTEIN TRANSPORT 9 381 5.497e-06 9.688e-05
265 NEGATIVE REGULATION OF CATABOLIC PROCESS 7 203 5.745e-06 0.0001009
266 B CELL ACTIVATION 6 132 5.771e-06 0.0001009
267 NEGATIVE REGULATION OF NECROTIC CELL DEATH 3 11 6.083e-06 0.0001056
268 POSITIVE REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS 3 11 6.083e-06 0.0001056
269 POSITIVE REGULATION OF MAP KINASE ACTIVITY 7 207 6.529e-06 0.0001129
270 POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY 4 36 6.631e-06 0.0001143
271 ACTIVATION OF MAPK ACTIVITY 6 137 7.148e-06 0.0001227
272 GLYCEROPHOSPHOLIPID METABOLIC PROCESS 8 297 7.348e-06 0.0001257
273 INSULIN RECEPTOR SIGNALING PATHWAY 5 80 7.721e-06 0.0001316
274 REGULATION OF ENDOTHELIAL CELL DEVELOPMENT 3 12 8.091e-06 0.0001369
275 REGULATION OF ESTABLISHMENT OF ENDOTHELIAL BARRIER 3 12 8.091e-06 0.0001369
276 JNK CASCADE 5 82 8.718e-06 0.0001464
277 REGULATION OF PROTEIN MATURATION 5 82 8.718e-06 0.0001464
278 CELLULAR COMPONENT DISASSEMBLY 10 515 8.946e-06 0.0001497
279 REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS 7 218 9.157e-06 0.0001527
280 REGULATION OF PROTEIN TARGETING 8 307 9.352e-06 0.0001554
281 RESPONSE TO IONIZING RADIATION 6 145 9.898e-06 0.0001639
282 REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY 4 40 1.018e-05 0.000168
283 REGULATION OF RESPONSE TO WOUNDING 9 413 1.05e-05 0.0001721
284 POSITIVE REGULATION OF MACROPHAGE DIFFERENTIATION 3 13 1.049e-05 0.0001721
285 RESPONSE TO TEMPERATURE STIMULUS 6 148 1.113e-05 0.0001817
286 REGULATION OF NIK NF KAPPAB SIGNALING 4 42 1.241e-05 0.0002012
287 POSITIVE REGULATION OF GLUCOSE TRANSPORT 4 42 1.241e-05 0.0002012
288 REGULATION OF CAMP DEPENDENT PROTEIN KINASE ACTIVITY 3 14 1.332e-05 0.0002152
289 REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY 4 43 1.365e-05 0.0002197
290 RESPONSE TO ENDOPLASMIC RETICULUM STRESS 7 233 1.41e-05 0.0002263
291 MITOCHONDRIAL MEMBRANE ORGANIZATION 5 92 1.531e-05 0.0002447
292 REGULATION OF PROTEIN LOCALIZATION 13 950 1.594e-05 0.000254
293 NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 9 437 1.646e-05 0.0002614
294 APOPTOTIC DNA FRAGMENTATION 3 15 1.661e-05 0.0002629
295 NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 11 684 1.796e-05 0.0002832
296 RESPONSE TO ANTIBIOTIC 4 47 1.952e-05 0.0003069
297 REGULATION OF LIPID KINASE ACTIVITY 4 48 2.124e-05 0.0003328
298 REGULATION OF AUTOPHAGY 7 249 2.164e-05 0.0003379
299 PROTEIN COMPLEX BIOGENESIS 14 1132 2.225e-05 0.0003451
300 PROTEIN COMPLEX ASSEMBLY 14 1132 2.225e-05 0.0003451
301 REGULATION OF GLUCOSE TRANSPORT 5 100 2.295e-05 0.0003547
302 CELLULAR RESPONSE TO LIPID 9 457 2.342e-05 0.0003597
303 CELLULAR PROCESS INVOLVED IN REPRODUCTION IN MULTICELLULAR ORGANISM 7 252 2.337e-05 0.0003597
304 REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS 3 17 2.47e-05 0.0003757
305 ACTIVATION OF NF KAPPAB INDUCING KINASE ACTIVITY 3 17 2.47e-05 0.0003757
306 NEGATIVE REGULATION OF ANOIKIS 3 17 2.47e-05 0.0003757
307 NEGATIVE REGULATION OF NEURON DEATH 6 171 2.525e-05 0.0003828
308 GLYCEROLIPID METABOLIC PROCESS 8 356 2.716e-05 0.000409
309 RESPONSE TO NICOTINE 4 51 2.707e-05 0.000409
310 LEUKOCYTE MIGRATION 7 259 2.785e-05 0.000418
311 HOMEOSTASIS OF NUMBER OF CELLS 6 175 2.877e-05 0.0004304
312 INOSITOL PHOSPHATE MEDIATED SIGNALING 3 18 2.957e-05 0.000441
313 RESPONSE TO GROWTH FACTOR 9 475 3.169e-05 0.0004712
314 PHOSPHOLIPID METABOLIC PROCESS 8 364 3.181e-05 0.0004714
315 DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION 10 602 3.421e-05 0.0005053
316 RESPONSE TO MUSCLE STRETCH 3 19 3.503e-05 0.000511
317 NEGATIVE REGULATION OF MEIOTIC CELL CYCLE 3 19 3.503e-05 0.000511
318 RESPONSE TO HYDROGEN PEROXIDE 5 109 3.478e-05 0.000511
319 DNA CATABOLIC PROCESS ENDONUCLEOLYTIC 3 19 3.503e-05 0.000511
320 REGULATION OF MYELOID CELL DIFFERENTIATION 6 183 3.696e-05 0.0005375
321 CELL CELL ADHESION 10 608 3.72e-05 0.0005392
322 REGULATION OF MACROPHAGE DIFFERENTIATION 3 20 4.112e-05 0.0005941
323 INNATE IMMUNE RESPONSE 10 619 4.327e-05 0.0006234
324 MYELOID CELL DIFFERENTIATION 6 189 4.427e-05 0.0006357
325 RESPONSE TO STEROID HORMONE 9 497 4.506e-05 0.0006452
326 B CELL HOMEOSTASIS 3 21 4.785e-05 0.000683
327 PROTEIN AUTOPHOSPHORYLATION 6 192 4.833e-05 0.0006877
328 REGULATION OF CELL ADHESION 10 629 4.951e-05 0.0007024
329 REGULATION OF GLUCOSE IMPORT 4 60 5.163e-05 0.00073
330 REGULATION OF BODY FLUID LEVELS 9 506 5.177e-05 0.00073
331 CELLULAR LIPID METABOLIC PROCESS 12 913 5.234e-05 0.0007357
332 REGULATION OF PHOSPHOLIPID METABOLIC PROCESS 4 61 5.511e-05 0.0007723
333 RELEASE OF CYTOCHROME C FROM MITOCHONDRIA 3 22 5.527e-05 0.0007723
334 REGULATION OF EPITHELIAL CELL DIFFERENTIATION 5 122 5.964e-05 0.0008309
335 REGULATION OF RESPONSE TO EXTERNAL STIMULUS 12 926 5.997e-05 0.000833
336 T CELL DIFFERENTIATION 5 123 6.2e-05 0.0008587
337 RESPONSE TO INSULIN 6 205 6.952e-05 0.0009599
338 REGULATION OF LEUKOCYTE PROLIFERATION 6 206 7.142e-05 0.0009832
339 REGULATION OF ANOIKIS 3 24 7.229e-05 0.0009922
340 REGULATION OF CELL CYCLE 12 949 7.586e-05 0.001032
341 INTERSPECIES INTERACTION BETWEEN ORGANISMS 10 662 7.586e-05 0.001032
342 SYMBIOSIS ENCOMPASSING MUTUALISM THROUGH PARASITISM 10 662 7.586e-05 0.001032
343 LIPID MODIFICATION 6 210 7.942e-05 0.001077
344 REGULATION OF HOMOTYPIC CELL CELL ADHESION 7 307 8.158e-05 0.001103
345 APOPTOTIC NUCLEAR CHANGES 3 25 8.195e-05 0.001105
346 REGULATION OF CELLULAR LOCALIZATION 14 1277 8.294e-05 0.001115
347 REGULATION OF TRANSPORT 17 1804 8.348e-05 0.001119
348 NEGATIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY 4 68 8.448e-05 0.00113
349 POSITIVE REGULATION OF CELL PROLIFERATION 11 814 8.722e-05 0.001163
350 REGULATION OF HEMOPOIESIS 7 314 9.39e-05 0.001248
351 POSITIVE REGULATION OF TYPE I INTERFERON PRODUCTION 4 70 9.463e-05 0.001254
352 NEGATIVE REGULATION OF NEURON APOPTOTIC PROCESS 5 135 9.641e-05 0.001274
353 REGULATION OF MITOCHONDRION ORGANIZATION 6 218 9.757e-05 0.001282
354 RESPONSE TO ESTROGEN 6 218 9.757e-05 0.001282
355 CELLULAR RESPONSE TO RADIATION 5 137 0.0001033 0.001355
356 REGULATION OF ENDOTHELIAL CELL DIFFERENTIATION 3 27 0.0001037 0.001356
357 POSITIVE REGULATION OF DEVELOPMENTAL PROCESS 13 1142 0.0001065 0.001389
358 REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING 5 138 0.0001069 0.00139
359 NEGATIVE REGULATION OF CELL CYCLE 8 433 0.0001074 0.001391
360 REGULATION OF CELLULAR RESPONSE TO STRESS 10 691 0.0001081 0.001397
361 RESPONSE TO COPPER ION 3 28 0.0001159 0.001494
362 POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 13 1152 0.0001163 0.001495
363 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY 4 74 0.0001176 0.001507
364 NEGATIVE REGULATION OF PROTEOLYSIS 7 329 0.0001254 0.001604
365 REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY 3 29 0.0001289 0.00163
366 POSITIVE REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY 3 29 0.0001289 0.00163
367 POSITIVE REGULATION OF NIK NF KAPPAB SIGNALING 3 29 0.0001289 0.00163
368 MUSCLE ADAPTATION 3 29 0.0001289 0.00163
369 POSITIVE REGULATION OF ORGANELLE ORGANIZATION 9 573 0.0001336 0.001685
370 REGULATION OF LEUKOCYTE DIFFERENTIATION 6 232 0.0001372 0.001725
371 RESPONSE TO ESTRADIOL 5 146 0.0001394 0.001743
372 CELLULAR RESPONSE TO INSULIN STIMULUS 5 146 0.0001394 0.001743
373 ORGANOPHOSPHATE BIOSYNTHETIC PROCESS 8 450 0.0001399 0.001746
374 TISSUE DEVELOPMENT 15 1518 0.0001424 0.001771
375 NEGATIVE REGULATION OF B CELL ACTIVATION 3 30 0.0001429 0.001773
376 RESPONSE TO TRANSITION METAL NANOPARTICLE 5 148 0.0001486 0.001838
377 CELLULAR RESPONSE TO DNA DAMAGE STIMULUS 10 720 0.0001513 0.001867
378 PROTEIN COMPLEX SUBUNIT ORGANIZATION 15 1527 0.000152 0.001871
379 REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS 5 152 0.0001683 0.002066
380 MITOCHONDRION ORGANIZATION 9 594 0.000175 0.002143
381 GAMETE GENERATION 9 595 0.0001772 0.002164
382 NEGATIVE REGULATION OF PEPTIDASE ACTIVITY 6 245 0.0001844 0.002246
383 EMBRYO DEVELOPMENT 11 894 0.0001988 0.002415
384 NEGATIVE REGULATION OF KINASE ACTIVITY 6 250 0.0002057 0.002493
385 PROTEIN KINASE B SIGNALING 3 34 0.0002086 0.002514
386 CELLULAR RESPONSE TO ALKALOID 3 34 0.0002086 0.002514
387 MACROMOLECULAR COMPLEX ASSEMBLY 14 1398 0.0002155 0.00259
388 NEGATIVE REGULATION OF PROTEIN PROCESSING 3 35 0.0002276 0.002722
389 NEGATIVE REGULATION OF PROTEIN MATURATION 3 35 0.0002276 0.002722
390 RESPONSE TO HEAT 4 89 0.0002401 0.002857
391 B CELL DIFFERENTIATION 4 89 0.0002401 0.002857
392 CALCIUM MEDIATED SIGNALING 4 90 0.0002506 0.002975
393 MULTICELLULAR ORGANISM REPRODUCTION 10 768 0.0002546 0.003015
394 POSITIVE REGULATION OF MITOCHONDRION ORGANIZATION 5 167 0.0002606 0.003078
395 TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY 8 498 0.0002785 0.003281
396 REGULATION OF CYTOKINE BIOSYNTHETIC PROCESS 4 94 0.0002961 0.003479
397 REGULATION OF CELL CELL ADHESION 7 380 0.0003028 0.003549
398 STRIATED MUSCLE CELL DIFFERENTIATION 5 173 0.0003067 0.003586
399 FC GAMMA RECEPTOR SIGNALING PATHWAY 4 95 0.0003083 0.003586
400 REGULATION OF LIPID TRANSPORT 4 95 0.0003083 0.003586
401 WNT SIGNALING PATHWAY CALCIUM MODULATING PATHWAY 3 39 0.0003147 0.003643
402 SPLEEN DEVELOPMENT 3 39 0.0003147 0.003643
403 EPITHELIUM DEVELOPMENT 11 945 0.0003203 0.003696
404 FEMALE GAMETE GENERATION 4 96 0.0003209 0.003696
405 REGULATION OF MEIOTIC CELL CYCLE 3 40 0.0003394 0.00389
406 REGULATION OF ACTIVATED T CELL PROLIFERATION 3 40 0.0003394 0.00389
407 MITOCHONDRIAL TRANSPORT 5 177 0.0003407 0.003896
408 MITOTIC SPINDLE ASSEMBLY 3 41 0.0003653 0.004156
409 MICROTUBULE CYTOSKELETON ORGANIZATION INVOLVED IN MITOSIS 3 41 0.0003653 0.004156
410 REPRODUCTION 13 1297 0.0003725 0.004227
411 RESPONSE TO LIGHT STIMULUS 6 280 0.0003774 0.004273
412 GLAND DEVELOPMENT 7 395 0.0003823 0.004318
413 REGULATION OF TUMOR NECROSIS FACTOR SUPERFAMILY CYTOKINE PRODUCTION 4 101 0.0003894 0.004387
414 MUSCLE SYSTEM PROCESS 6 282 0.000392 0.004406
415 NEGATIVE REGULATION OF HYDROLASE ACTIVITY 7 397 0.0003941 0.004418
416 POSITIVE REGULATION OF CELL DIFFERENTIATION 10 823 0.0004405 0.004927
417 REGULATION OF RELEASE OF CYTOCHROME C FROM MITOCHONDRIA 3 44 0.0004506 0.005028
418 LIPID BIOSYNTHETIC PROCESS 8 539 0.0004719 0.00524
419 PROTEIN DEPHOSPHORYLATION 5 190 0.0004713 0.00524
420 POSITIVE REGULATION OF INTERLEUKIN 8 PRODUCTION 3 45 0.0004816 0.005294
421 THYMOCYTE AGGREGATION 3 45 0.0004816 0.005294
422 NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 8 541 0.0004836 0.005294
423 LIPID METABOLIC PROCESS 12 1158 0.0004798 0.005294
424 T CELL DIFFERENTIATION IN THYMUS 3 45 0.0004816 0.005294
425 NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 8 541 0.0004836 0.005294
426 REGULATION OF CELL CYCLE ARREST 4 108 0.0005021 0.005471
427 REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION 4 108 0.0005021 0.005471
428 ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY 9 689 0.0005198 0.005651
429 REGULATION OF TYPE I INTERFERON PRODUCTION 4 111 0.0005568 0.006039
430 EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING 8 554 0.0005654 0.006118
431 NEGATIVE REGULATION OF PHOSPHORYLATION 7 422 0.000567 0.006122
432 REGULATION OF CELL CYCLE PROCESS 8 558 0.0005927 0.006384
433 OVULATION CYCLE 4 113 0.0005956 0.0064
434 REGULATION OF TOLL LIKE RECEPTOR SIGNALING PATHWAY 3 49 0.0006192 0.006639
435 POSITIVE REGULATION OF CELL ACTIVATION 6 311 0.0006564 0.006998
436 FEMALE SEX DIFFERENTIATION 4 116 0.0006573 0.006998
437 POSITIVE REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION 3 50 0.0006572 0.006998
438 BIOLOGICAL ADHESION 11 1032 0.0006719 0.007138
439 NEGATIVE REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING 3 51 0.0006966 0.007366
440 REGULATION OF INTERLEUKIN 12 PRODUCTION 3 51 0.0006966 0.007366
441 REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION 4 118 0.0007008 0.007395
442 GERM CELL DEVELOPMENT 5 209 0.0007258 0.007641
443 REGULATION OF VITAMIN METABOLIC PROCESS 2 12 0.0007354 0.007676
444 REGULATION OF T CELL MEDIATED IMMUNITY 3 52 0.0007374 0.007676
445 I KAPPAB PHOSPHORYLATION 2 12 0.0007354 0.007676
446 POSITIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY 3 52 0.0007374 0.007676
447 POSITIVE REGULATION OF INTERLEUKIN 2 BIOSYNTHETIC PROCESS 2 12 0.0007354 0.007676
448 REGULATION OF B CELL ACTIVATION 4 121 0.00077 0.007997
449 CELLULAR RESPONSE TO AMINO ACID STIMULUS 3 53 0.0007798 0.008081
450 SEXUAL REPRODUCTION 9 730 0.0007858 0.008125
451 REGULATION OF HOMEOSTATIC PROCESS 7 447 0.0007958 0.008211
452 TUBE MORPHOGENESIS 6 323 0.0007995 0.00823
453 SYSTEM PROCESS 15 1785 0.0008091 0.008311
454 NEGATIVE REGULATION OF REPRODUCTIVE PROCESS 3 54 0.0008236 0.008386
455 REGULATION OF LYMPHOCYTE APOPTOTIC PROCESS 3 54 0.0008236 0.008386
456 REGULATION OF MITOCHONDRIAL MEMBRANE POTENTIAL 3 54 0.0008236 0.008386
457 B CELL RECEPTOR SIGNALING PATHWAY 3 54 0.0008236 0.008386
458 HEPATOCYTE APOPTOTIC PROCESS 2 13 0.0008672 0.008715
459 POSITIVE REGULATION OF ENDOPLASMIC RETICULUM UNFOLDED PROTEIN RESPONSE 2 13 0.0008672 0.008715
460 REGULATION OF HISTONE PHOSPHORYLATION 2 13 0.0008672 0.008715
461 REGULATION OF B CELL PROLIFERATION 3 55 0.000869 0.008715
462 REGULATION OF PROTEIN POLYUBIQUITINATION 2 13 0.0008672 0.008715
463 PROTEIN AUTOPROCESSING 2 13 0.0008672 0.008715
464 REGULATION OF BICELLULAR TIGHT JUNCTION ASSEMBLY 2 13 0.0008672 0.008715
465 POSITIVE REGULATION OF TUMOR NECROSIS FACTOR SUPERFAMILY CYTOKINE PRODUCTION 3 57 0.0009645 0.009631
466 APOPTOTIC MITOCHONDRIAL CHANGES 3 57 0.0009645 0.009631
NumGOOverlapSizeP ValueAdj. P Value
1 DEATH RECEPTOR BINDING 8 18 4.967e-16 2.307e-13
2 TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY BINDING 10 47 4.849e-16 2.307e-13
3 CYTOKINE RECEPTOR BINDING 15 271 1.51e-14 4.676e-12
4 KINASE ACTIVITY 22 842 2.646e-14 4.917e-12
5 CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC PROCESS 7 15 2.407e-14 4.917e-12
6 ENZYME BINDING 28 1737 5.029e-13 7.786e-11
7 TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS 22 992 7.21e-13 9.568e-11
8 CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 9 86 1.311e-11 1.522e-09
9 PROTEIN SERINE THREONINE KINASE ACTIVITY 15 445 1.937e-11 1.999e-09
10 PROTEIN HETERODIMERIZATION ACTIVITY 15 468 3.938e-11 3.658e-09
11 UBIQUITIN LIKE PROTEIN LIGASE BINDING 12 264 8.239e-11 6.959e-09
12 PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY 8 70 9.326e-11 7.22e-09
13 X1 PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY 7 43 1.118e-10 7.992e-09
14 PROTEIN KINASE ACTIVITY 16 640 3.145e-10 2.087e-08
15 PHOSPHATIDYLINOSITOL KINASE ACTIVITY 7 51 3.933e-10 2.436e-08
16 PROTEIN DOMAIN SPECIFIC BINDING 15 624 2.1e-09 1.219e-07
17 CYSTEINE TYPE PEPTIDASE ACTIVITY 9 184 1.199e-08 6.188e-07
18 IDENTICAL PROTEIN BINDING 19 1209 1.196e-08 6.188e-07
19 KINASE REGULATOR ACTIVITY 9 186 1.317e-08 6.441e-07
20 ADENYL NUCLEOTIDE BINDING 21 1514 1.488e-08 6.911e-07
21 PROTEIN DIMERIZATION ACTIVITY 18 1149 3.345e-08 1.48e-06
22 TUMOR NECROSIS FACTOR RECEPTOR BINDING 5 30 5.219e-08 2.204e-06
23 PROTEASE BINDING 7 104 6.263e-08 2.53e-06
24 ENZYME REGULATOR ACTIVITY 16 959 9.667e-08 3.742e-06
25 KINASE BINDING 13 606 1.085e-07 4.031e-06
26 INTERLEUKIN 1 RECEPTOR BINDING 4 16 2.157e-07 7.706e-06
27 CYSTEINE TYPE ENDOPEPTIDASE REGULATOR ACTIVITY INVOLVED IN APOPTOTIC PROCESS 5 42 3.019e-07 1.039e-05
28 MOLECULAR FUNCTION REGULATOR 18 1353 3.889e-07 1.29e-05
29 RIBONUCLEOTIDE BINDING 21 1860 4.987e-07 1.598e-05
30 DEATH RECEPTOR ACTIVITY 4 24 1.234e-06 3.82e-05
31 RECEPTOR BINDING 18 1476 1.38e-06 4.137e-05
32 PROTEIN COMPLEX BINDING 14 935 2.518e-06 7.309e-05
33 PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY 4 30 3.133e-06 8.82e-05
34 INSULIN RECEPTOR SUBSTRATE BINDING 3 11 6.083e-06 0.0001662
35 PROTEIN KINASE A BINDING 4 42 1.241e-05 0.0003294
36 HEAT SHOCK PROTEIN BINDING 5 89 1.302e-05 0.000336
37 PROTEIN KINASE A CATALYTIC SUBUNIT BINDING 3 15 1.661e-05 0.0004171
38 PHOSPHATIDYLINOSITOL PHOSPHATE KINASE ACTIVITY 3 16 2.039e-05 0.0004858
39 ENDOPEPTIDASE ACTIVITY 9 448 2.003e-05 0.0004858
40 PROTEIN HOMODIMERIZATION ACTIVITY 11 722 2.954e-05 0.0006861
41 ENZYME INHIBITOR ACTIVITY 8 378 4.156e-05 0.0009418
42 MACROMOLECULAR COMPLEX BINDING 15 1399 5.679e-05 0.001256
43 CAMP BINDING 3 23 6.341e-05 0.001339
44 CYSTEINE TYPE ENDOPEPTIDASE INHIBITOR ACTIVITY INVOLVED IN APOPTOTIC PROCESS 3 23 6.341e-05 0.001339
45 PROTEIN SERINE THREONINE PHOSPHATASE ACTIVITY 4 64 6.659e-05 0.001375
46 GROWTH FACTOR RECEPTOR BINDING 5 129 7.775e-05 0.00157
47 PEPTIDASE REGULATOR ACTIVITY 6 214 8.812e-05 0.001742
48 SIGNAL TRANSDUCER ACTIVITY 16 1731 0.0001777 0.003439
49 KINASE INHIBITOR ACTIVITY 4 89 0.0002401 0.004552
50 CYCLIC NUCLEOTIDE BINDING 3 36 0.0002477 0.004602
51 PEPTIDASE ACTIVITY 9 663 0.0003935 0.007167
52 SCAFFOLD PROTEIN BINDING 3 45 0.0004816 0.008604
NumGOOverlapSizeP ValueAdj. P Value
1 MEMBRANE MICRODOMAIN 17 288 7.131e-17 4.165e-14
2 TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS 15 237 2.078e-15 6.068e-13
3 CATALYTIC COMPLEX 24 1038 1.892e-14 3.684e-12
4 MEMBRANE PROTEIN COMPLEX 23 1020 1.313e-13 1.918e-11
5 PHOSPHATIDYLINOSITOL 3 KINASE COMPLEX 7 20 2.861e-13 3.342e-11
6 PROTEIN KINASE COMPLEX 8 90 7.259e-10 7.065e-08
7 CYTOSOLIC PART 10 223 4.013e-09 3.348e-07
8 TRANSFERASE COMPLEX 15 703 1.046e-08 7.637e-07
9 CILIARY BASE 5 23 1.255e-08 8.145e-07
10 PLASMA MEMBRANE PROTEIN COMPLEX 13 510 1.444e-08 8.431e-07
11 MEMBRANE REGION 18 1134 2.736e-08 1.453e-06
12 CD40 RECEPTOR COMPLEX 3 11 6.083e-06 0.0002733
13 IKAPPAB KINASE COMPLEX 3 11 6.083e-06 0.0002733
14 RECEPTOR COMPLEX 8 327 1.477e-05 0.0006161
15 PHOSPHATASE COMPLEX 4 48 2.124e-05 0.0008271
16 EXTRINSIC COMPONENT OF MEMBRANE 7 252 2.337e-05 0.000853
17 MITOCHONDRION 16 1633 8.99e-05 0.003088
18 PLASMA MEMBRANE RAFT 4 86 0.0002104 0.006827
19 PLASMA MEMBRANE RECEPTOR COMPLEX 5 175 0.0003234 0.009443
20 PERINUCLEAR REGION OF CYTOPLASM 9 642 0.000311 0.009443

Over-represented Pathway

NumPathwayPathviewOverlapSizeP ValueAdj. P Value
1 hsa04210_Apoptosis 68 89 1.227e-176 2.172e-174
2 hsa04620_Toll.like_receptor_signaling_pathway 22 102 1.089e-34 9.636e-33
3 hsa04380_Osteoclast_differentiation 22 128 2.574e-32 1.519e-30
4 hsa04722_Neurotrophin_signaling_pathway 21 127 1.872e-30 8.284e-29
5 hsa04662_B_cell_receptor_signaling_pathway 18 75 2.617e-29 9.266e-28
6 hsa04660_T_cell_receptor_signaling_pathway 19 108 4.202e-28 1.24e-26
7 hsa04010_MAPK_signaling_pathway 22 268 6.065e-25 1.534e-23
8 hsa04062_Chemokine_signaling_pathway 18 189 1.338e-21 2.959e-20
9 hsa04650_Natural_killer_cell_mediated_cytotoxicity 16 136 9.188e-21 1.807e-19
10 hsa04910_Insulin_signaling_pathway 16 138 1.171e-20 2.073e-19
11 hsa04370_VEGF_signaling_pathway 13 76 3.111e-19 5.006e-18
12 hsa04621_NOD.like_receptor_signaling_pathway 11 59 7.395e-17 1.091e-15
13 hsa04914_Progesterone.mediated_oocyte_maturation 12 87 1.248e-16 1.699e-15
14 hsa04622_RIG.I.like_receptor_signaling_pathway 11 71 6.556e-16 8.289e-15
15 hsa04510_Focal_adhesion 14 200 4.851e-15 5.725e-14
16 hsa04973_Carbohydrate_digestion_and_absorption 9 44 2.26e-14 2.5e-13
17 hsa04920_Adipocytokine_signaling_pathway 10 68 2.576e-14 2.682e-13
18 hsa04150_mTOR_signaling_pathway 9 52 1.148e-13 1.129e-12
19 hsa04115_p53_signaling_pathway 9 69 1.69e-12 1.575e-11
20 hsa04630_Jak.STAT_signaling_pathway 11 155 4.44e-12 3.929e-11
21 hsa04664_Fc_epsilon_RI_signaling_pathway 9 79 5.977e-12 5.038e-11
22 hsa04623_Cytosolic_DNA.sensing_pathway 8 56 1.457e-11 1.122e-10
23 hsa04012_ErbB_signaling_pathway 9 87 1.458e-11 1.122e-10
24 hsa04666_Fc_gamma_R.mediated_phagocytosis 9 95 3.27e-11 2.412e-10
25 hsa04960_Aldosterone.regulated_sodium_reabsorption 7 42 9.388e-11 6.647e-10
26 hsa04070_Phosphatidylinositol_signaling_system 7 78 8.35e-09 5.684e-08
27 hsa04720_Long.term_potentiation 6 70 1.363e-07 8.928e-07
28 hsa04670_Leukocyte_transendothelial_migration 7 117 1.412e-07 8.928e-07
29 hsa04114_Oocyte_meiosis 6 114 2.466e-06 1.505e-05
30 hsa04810_Regulation_of_actin_cytoskeleton 7 214 8.115e-06 4.788e-05
31 hsa04310_Wnt_signaling_pathway 6 151 1.248e-05 7.124e-05
32 hsa04020_Calcium_signaling_pathway 6 177 3.066e-05 0.0001696
33 hsa04962_Vasopressin.regulated_water_reabsorption 3 44 0.0004506 0.002417
34 hsa04742_Taste_transduction 3 52 0.0007374 0.003839
35 hsa04340_Hedgehog_signaling_pathway 3 56 0.000916 0.004632
36 hsa00562_Inositol_phosphate_metabolism 3 57 0.0009645 0.004742
37 hsa04976_Bile_secretion 3 71 0.001821 0.008713
38 hsa04971_Gastric_acid_secretion 3 74 0.002051 0.009552
39 hsa04141_Protein_processing_in_endoplasmic_reticulum 4 168 0.002576 0.01169
40 hsa04640_Hematopoietic_cell_lineage 3 88 0.003356 0.01485
41 hsa04970_Salivary_secretion 3 89 0.003465 0.01496
42 hsa04540_Gap_junction 3 90 0.003576 0.01507
43 hsa04912_GnRH_signaling_pathway 3 101 0.004939 0.01987
44 hsa04916_Melanogenesis 3 101 0.004939 0.01987
45 hsa04270_Vascular_smooth_muscle_contraction 3 116 0.007246 0.0285
46 hsa04360_Axon_guidance 3 130 0.009889 0.03805
47 hsa04120_Ubiquitin_mediated_proteolysis 3 139 0.01185 0.04462
48 hsa04530_Tight_junction 2 133 0.07527 0.2776
49 hsa04740_Olfactory_transduction 3 388 0.1455 0.5255

lncRNA-mediated sponge

(Download full result)

Num lncRNA miRNAs           miRNAs count     Gene Sponge regulatory network lncRNA log2FC lncRNA pvalue Gene log2FC Gene pvalue lncRNA-gene Pearson correlation
1 DGCR5 hsa-miR-107;hsa-miR-139-5p;hsa-miR-140-5p;hsa-miR-186-5p;hsa-miR-190a-5p;hsa-miR-192-5p;hsa-miR-215-5p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-362-3p;hsa-miR-375;hsa-miR-577 13 IL1RAP Sponge network 1.383 0.01835 1.199 0.00709 0.476
2

RFPL1S

 hsa-miR-106b-5p;hsa-miR-107;hsa-miR-16-5p;hsa-miR-17-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-320b;hsa-miR-335-3p;hsa-miR-33a-3p;hsa-miR-362-3p;hsa-miR-3662;hsa-miR-501-3p;hsa-miR-502-3p;hsa-miR-505-3p 14 AKT3 Sponge network -0.223 0.70704 -0.749 0.06936 0.466
3

PLAC4

 hsa-miR-125b-2-3p;hsa-miR-125b-5p;hsa-miR-149-5p;hsa-miR-181a-2-3p;hsa-miR-23a-3p;hsa-miR-23b-3p;hsa-miR-27a-3p;hsa-miR-27b-3p;hsa-miR-708-3p;hsa-miR-9-3p 10 XIAP Sponge network -0.563 0.27163 0.189 0.26753 0.418
4

FAM66C

 hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-29a-5p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-590-5p 11 BCL2 Sponge network -0.353 0.40349 -1.094 0.00317 0.407
5

MIAT

 hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-215-5p;hsa-miR-3065-5p;hsa-miR-7-5p 10 BCL2 Sponge network 0.534 0.20962 -1.094 0.00317 0.385
6

RFPL1S

 hsa-miR-126-5p;hsa-miR-17-3p;hsa-miR-181b-5p;hsa-miR-186-5p;hsa-miR-192-5p;hsa-miR-215-5p;hsa-miR-26b-5p;hsa-miR-30d-3p;hsa-miR-335-3p;hsa-miR-3662 10 IL1R1 Sponge network -0.223 0.70704 -0.907 0.00472 0.367
7

EMX2OS

 hsa-miR-106b-5p;hsa-miR-107;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-32-3p;hsa-miR-335-3p;hsa-miR-362-3p;hsa-miR-421;hsa-miR-424-5p;hsa-miR-501-3p;hsa-miR-502-3p;hsa-miR-505-3p;hsa-miR-577;hsa-miR-616-5p;hsa-miR-93-5p 19 AKT3 Sponge network -1.088 0.10042 -0.749 0.06936 0.354
8

NEAT1

 hsa-miR-130a-3p;hsa-miR-130b-3p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-224-3p;hsa-miR-224-5p;hsa-miR-301a-3p;hsa-miR-34c-5p;hsa-miR-484;hsa-miR-708-5p;hsa-miR-9-5p 11 CFLAR Sponge network -0.686 0.02293 0.072 0.73819 0.345
9

RFPL1S

 hsa-miR-126-5p;hsa-miR-146a-5p;hsa-miR-148a-5p;hsa-miR-148b-3p;hsa-miR-186-5p;hsa-miR-200b-3p;hsa-miR-29b-1-5p;hsa-miR-320b;hsa-miR-320c;hsa-miR-335-3p;hsa-miR-335-5p;hsa-miR-7-1-3p 12 PIK3CA Sponge network -0.223 0.70704 0.181 0.37992 0.345
10 KCNQ1OT1 hsa-miR-125b-2-3p;hsa-miR-125b-5p;hsa-miR-149-5p;hsa-miR-181a-2-3p;hsa-miR-23a-3p;hsa-miR-23b-3p;hsa-miR-27a-3p;hsa-miR-27b-3p;hsa-miR-708-3p;hsa-miR-9-3p 10 XIAP Sponge network -0.725 0.08874 0.189 0.26753 0.342
11

EMX2OS

 hsa-let-7f-1-3p;hsa-miR-107;hsa-miR-186-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-32-5p;hsa-miR-335-3p;hsa-miR-590-3p;hsa-miR-92a-3p;hsa-miR-92b-3p 10 PRKAR2B Sponge network -1.088 0.10042 -2.312 0 0.34
12

MIAT

 hsa-miR-106b-5p;hsa-miR-107;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-3065-5p;hsa-miR-32-3p;hsa-miR-320b;hsa-miR-33a-3p;hsa-miR-3662;hsa-miR-501-3p;hsa-miR-502-3p 11 AKT3 Sponge network 0.534 0.20962 -0.749 0.06936 0.335
13

MEG3

 hsa-miR-106b-5p;hsa-miR-107;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-32-3p;hsa-miR-320b;hsa-miR-335-3p;hsa-miR-33a-3p;hsa-miR-3662;hsa-miR-577;hsa-miR-616-5p;hsa-miR-93-5p 16 AKT3 Sponge network -1.645 0.00049 -0.749 0.06936 0.312
14

PCA3

 hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-128-3p;hsa-miR-144-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-188-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-224-3p;hsa-miR-32-3p;hsa-miR-320b;hsa-miR-324-3p;hsa-miR-330-3p;hsa-miR-424-5p;hsa-miR-532-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p;hsa-miR-96-5p 31 PIK3R1 Sponge network -2.778 8.0E-5 -1.094 2.0E-5 0.309
15

RFPL1S

 hsa-miR-16-2-3p;hsa-miR-181b-5p;hsa-miR-192-5p;hsa-miR-196b-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-215-5p;hsa-miR-29a-5p;hsa-miR-335-3p;hsa-miR-34a-5p;hsa-miR-375;hsa-miR-429;hsa-miR-7-1-3p;hsa-miR-7-5p 17 BCL2 Sponge network -0.223 0.70704 -1.094 0.00317 0.308
16

PCA3

 hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-181b-5p;hsa-miR-196b-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-577;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-7-1-3p 15 BCL2 Sponge network -2.778 8.0E-5 -1.094 0.00317 0.306
17

PLAC4

 hsa-miR-205-5p;hsa-miR-20a-3p;hsa-miR-224-3p;hsa-miR-324-5p;hsa-miR-33a-5p;hsa-miR-33b-5p;hsa-miR-452-3p;hsa-miR-708-3p;hsa-miR-9-3p;hsa-miR-944 10 IRAK3 Sponge network -0.563 0.27163 -1.283 0.00693 0.295
18

AGAP11

 hsa-let-7f-1-3p;hsa-miR-126-5p;hsa-miR-146a-5p;hsa-miR-148a-5p;hsa-miR-148b-3p;hsa-miR-200b-3p;hsa-miR-29b-1-5p;hsa-miR-320b;hsa-miR-320c;hsa-miR-335-3p;hsa-miR-501-5p 11 PIK3CA Sponge network -1.728 0.00016 0.181 0.37992 0.282
19 CECR7 hsa-miR-192-5p;hsa-miR-196b-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-215-5p;hsa-miR-34a-5p;hsa-miR-429;hsa-miR-7-1-3p;hsa-miR-7-5p 10 BCL2 Sponge network -1.429 0.0775 -1.094 0.00317 0.276
20

FAM66C

 hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-200c-3p;hsa-miR-429;hsa-miR-590-5p 10 PRKACB Sponge network -0.353 0.40349 -2.003 0 0.273
21

AGAP11

 hsa-let-7f-1-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-2110;hsa-miR-3662;hsa-miR-421;hsa-miR-590-5p;hsa-miR-93-5p 10 PRKACB Sponge network -1.728 0.00016 -2.003 0 0.27
22

MALAT1

 hsa-miR-205-5p;hsa-miR-224-3p;hsa-miR-3200-3p;hsa-miR-335-3p;hsa-miR-33a-5p;hsa-miR-33b-5p;hsa-miR-421;hsa-miR-452-3p;hsa-miR-9-3p;hsa-miR-92b-3p;hsa-miR-944 11 IRAK3 Sponge network -1.099 0.0005 -1.283 0.00693 0.259
23

PCA3

 hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-146b-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-200c-3p;hsa-miR-32-3p;hsa-miR-330-3p;hsa-miR-3662;hsa-miR-577;hsa-miR-590-5p;hsa-miR-616-5p;hsa-miR-93-5p;hsa-miR-96-5p 18 PRKACB Sponge network -2.778 8.0E-5 -2.003 0 0.257
24

PART1

 hsa-miR-146a-5p;hsa-miR-186-5p;hsa-miR-29b-1-5p;hsa-miR-320b;hsa-miR-335-3p;hsa-miR-335-5p;hsa-miR-338-5p;hsa-miR-501-5p;hsa-miR-577;hsa-miR-7-1-3p 10 PIK3CA Sponge network -2.298 0.00168 0.181 0.37992 0.253

Quest ID: 4ccbb6111bb21556ec8a9ffcdc47e16b